Drug intelligence / Profile preview

3-TYP

Development stage: Preclinical
Modality: Small Molecules

Overview

3-TYP is a potent and selective small-molecule inhibitor of Sirtuin 3 (SIRT3), a mitochondrial NAD+-dependent deacetylase. By inhibiting SIRT3, 3-TYP disrupts mitochondrial metabolic homeostasis, leading to increased mitochondrial reactive oxygen species (mtROS) production and alterations in autophagy and mitophagy pathways. In preclinical models, particularly in triple-negative breast cancer (TNBC), 3-TYP has been shown to reduce spheroid growth and suppress the expression of oncogenic factors such as HIF-1α and c-Myc. It is frequently utilized as a pharmacological tool to investigate the role of SIRT3 in metabolic reprogramming, oxidative stress, and tumor progression.

Other names: 3-(1H-1,2,3-triazol-4-yl)pyridine

Targets

SIRT3 (NAD-dependent protein deacetylase sirtuin-3)

Beyond the preview

Go deeper on 3-TYP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-TYP.

Explore the full profile